Fig. 5
Schematic diagram of the clinical trial. All patients received weekly cAD-MSCs eye drops with 2 × 106 cells suspended in 50 μL PBS for 6 consecutive weeks. Participants took four complete ophthalmic examinations at baseline (0), 3rd, 6th and 9th week. The patients in refractory group were confirmed that had stopped applying immunosuppressant for at least 14 days